### The Australian Corneal Graft Registry 2019 Annual Report

Miriam Keane, PhD ACGR Executive Director At the Australia and New Zealand Cornea Society Meeting Auckland, New Zealand, February 2020

### Registered Grafts – 31<sup>st</sup> December 2019

		Registered	
	Total	38116 (100%)	
1985	РК	26101 (68%)	
onwards	Patch	1589 (4%)	
	Limbal	87 (<1%)	
2000	DALK	1825 (5%)	
Introduced in 2006	DS(A)EK	6144 (16%)	
2007	DMEK	2370 (6%)	

#### Followed Grafts – 31<sup>st</sup> December 2019

		Registered	Followed	
	Total	38116 (100%)	81%	
1985	РК	26101 (68%)	85%	
onwards	Patch	1589 (4%)	82%	
on a as	Limbal	87 (<1%)	78%	
<b>2000</b>	DALK	1825 (5%)	62%	
Introduced in 2006	DS(A)EK	6144 (16%)	76%	
2007	DMEK	2370 (6%)	57%	

#### Failed Grafts – 31<sup>st</sup> December 2019

		Registered	Followed	Failed
	Total	38116 (100%)	81%	22%
1985	РК	26101 (68%)	85%	24%
onwards	Patch	1589 (4%)	82%	21%
onwaras	Limbal	87 (<1%)	78%	35%
2000	DALK	1825 (5%)	62%	8%
Introduced in 2006	DS(A)EK	6144 (16%)	76%	19%
2007	DMEK	2370 (6%)	57%	18%


### Early/Primary Failures – 31<sup>st</sup> December 2019

		Registered	Followed	Failed	EGF*	PNF*
	Total	38116	81%	22%	4%	2%
1985	РК	26101 (68%)	85%	24%	2%	<1%
onwards	Patch	1589 (4%) 82%		21%	7%	1%
onwards	Limbal	87 (<1%)	78%	35%	6%	1%
2000	DALK	1825 (5%)	62%	8%	2%	1%
Introduced in 2006	DS(A)EK	6144 (16%)	76%	19%	5%	5%
2007	DMEK	2370 (6%)	57%	18%	11%	10%


\*EGF = Early graft failure, failed within 3 months of graft

PNF = Primary non-functioning graft, surgeon specified that graft never cleared/attached


### Primary Non-functioning Grafts (PNFG)




## Number of Grafts Registered



## First vs. Repeat Grafts by Graft Type



### Second Graft Following Failure of First PK




 Increased in second grafts per year
 1/3 are EK

#### **Reason for failure of first graft**

	PK:PK	PK:DS(A)EK	PK:DMEK
Endothelial failure	24%	53%	61%
Rejection	22%	28%	30%
Other specified	40%*	7%	5%
Not specified	14%	12%	5%

\*included: recurrent keratoconus/astigmatism (7%), non-herpetic infection (6%), ulcer (4%), scarring (3%), trauma (3%), herpetic infection (2%), glaucoma (2%), primary graft failure (2%), other (11%)


#### Second Graft Following Failure of First EK



## Differences in repeat graft survival depending on: graft type survival length of first graft

## Second Graft following PK


2006 onwards



	1 Year	2 Years	4 Years	6 Years	8 Years	10 Years	12 Years
РК	.94 (3596)	.90 (2640)	.81 (1454)	.73 (772)	.64 (329)	.53 (111)	.36 (25)
PK:PK	.93 (677)	.85 (506)	.68 (255)	.54 (124)	.37 (39)	.26 (10)	NA (1)

- For all data since 1985
  - 19,200 first vs 2,171 second
  - Chi<sup>2</sup> = 390.35, p<0.001</p>
- Still the case for 2006 onwards
  - Chi<sup>2</sup> = 75.09, p<0.001</p>


## Second Graft following PK



- No significant difference in survival for PK:PK following PNFG
- Still the case for 2006 onwards


	1 Year	2 Years	4 Years	6 Years	8 Years	10 Years	15 Years	20 Years
PK:FG:PK	.89 (1263)	.78 (918)	.63 (512)	.52 (309)	.42 (172)	.35 (102)	.22 (27)	.12 (12)
PK:PNFG:PK	.83 (80)	.71 (53)	.69 (38)	.56 (23)	.56 (15)	.52 (10)	NA (5)	NA (4)

## Visual outcomes - PK vs PK:PK



- Significant improvements
- First grafts reach 6/12 at 2 years and maintain
- Median BCVA worse following repeat grafts

#### Visual outcomes - PK vs PK:PK, surviving grafts




	Registered	Pre-graft	1 Year	2 Years	3 Years	4 Years	5 Years
РК	5832	5509	463	426	258	181	153
PK:PK (surviving)	1150	1070	81	59	38	33	20

- Excluding failures tightens interquartile ranges
- At 2 years
  - Repeat grafts reach 6/12
  - Comparable BCVA
- Repeat BCVA drops off
- Remain better than pre-graft
- Worse than first grafts

### Type of Second Graft following PK

#### 2006 onwards



	1 Year	2 Years	4 Years	6 Years	8 Years	10 Years
РК:РК	.93 (677)	.85 (506)	.68 (255)	.54 (125)	.37 (39)	.26 (10)
PK:DS(A)EK	.84 (106)	.72 (68)	.53 (30)	.44 (14)	NA (4)	NA (1)
PK:DMEK	.70 (23)	.56 (12)	NA(2)	NA (2)	NA	NA

Reasons for failure of second graft


	РК:РК	PK:DS(A)EK	PK:DMEK
PNFG	1%	20%	39%
Endothelial failure	24%	30%	34%
Rejection	27%	18%	15%
Infection	7%	5%	2%
Corneal ulcer	5%	2%	0%
Trauma	2%	2%	0%
Glaucoma	2%	2%	0%
Corneal scar	2%	1%	0%
Other specified	10%	8%	5%
Not specified	19%	12%	5%
Total	513 (100%)	122 (100%)	41 (100%)

#### Excluding PNFG, PK vs.DS(A)EK p=0.01, PK vs. DMEK p=0.138, DS(A)EK vs DMEK p=0.851


### Visual outcomes – Repeat following PK

#### 2006 onwards

- Surviving grafts only
- Median BCVA at 1 year 6/36
- Including failures at 1 year, DS(A)EK has BCVA of 6/60 (n=25), PK still 6/36 (n=96)




## Second Grafts following DS(A)EK




#### Following non-PNFG (n=298): p=0.021

## Visual outcomes – DS(A)EK




- All grafts (surviving and failed)
- Pre-graft BCVA worse in repeat grafts
- Similar median BCVA (6/15) at 1 year post PNFG to first DS(A)EK
- Poorer median BCVA at 1 year following longer term initial survival

## Visual outcomes – DS(A)EK



- Excluding failures
- Tighter interquartile ranges
- Improved median BCVA in repeats

## Second Grafts following DMEK



	3 Months	6 Months	1 Year	2 Years	3 Years	4 Years	5 Years	6 Years
DMEK	.81 (724)	.80 (653)	.77 (527)	.73 (281)	.68 (120)	.62 (44)	.54 (24)	NA (9)
DMEK:DMEK	.84 (98)	.78 (86)	.75 (75)	.71 (44)	.67 (26)	.65 (18)	.65 (11)	NA (3)
DMEK:DMEK (following PNFG)	.85 (75)	.80 (66)	.76 (56)	.74 (37)	.74 (24)	.71 (16)	.71 (10)	NA (3)
DMEK:DMEK (excluding PNFG)	.79 (23)	.72 (20)	.72 (19)	NA (7)	NA (2)	NA (2)	NA (1)	NA

#### Following non-PNFG (n=59): p=0.084

## Summary

- Rates of PNFG in DMEK continue to drop
- >50% of repeat grafts are EK
- Second PK exhibit poorer outcomes than first PK
- Outcomes of EK following first failed PK is poorer than repeat PK
- DS(A)EK:DS(A)EK have poorer outcome than first DS(A)EK
  This is NOT the case where the first graft was a PNFG
- There is no significant difference for DMEK:DMEK versus DMEK

# Take home message

For endothelial keratoplasty the primary non-function of a first graft does not adversely affect the outcomes of a second graft

## Acknowledgments

**DonateLife – The Australian Government Organ and Tissue Authority** 

Contributing surgeons, eye banks and follow-up practitioners

Our team

- Miriam Keane Executive Director
- Nora Coffey Project Officer
- Vicky Jones Administrative Officer
- Keryn Williams Scientific Director
- Richard Mills Medical Director





Australian Corneal Graft Registry

Phone: 08 8204 5321

Email: miriam.keane@flinders.edu.au

2018 report: http://hdl.handle.net/2328/37917

